Drugs / FWD1509
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05068024 | Aug 2021 → Oct 2022 | non-small cell lung carcinoma | Forward Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FWD1509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05068024 ↗ |
| Action | Inhibit | “blocks the function of tyrosine kinase.” NCT05068024 ↗ |
| Route | Oral | “FWD1509 MsOH is administered orally once daily.” NCT05068024 ↗ |
| Target | EGFR | “FWD1509 MsOH is new generation EGFR-TKI targeting EGFR mutations such as exon 19 deletion, L858R substitution as well as T790M mutations.” NCT05068024 ↗ |